Barclays
XBIO icon

Barclays’s Xenetic Biosciences XBIO Stock Holding History

Barclays’s Portfolio XBIO Stock Details XBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-224
Closed -$585 – 5582
2025
Q1 		$585 Buy
+224
New +$876 ﹤0.01% 5074
2019
Q3 		– Sell
-2
Closed – – 7180
2019
Q2 		$0 Hold
2
– – ﹤0.01% 7324
2019
Q1 		$0 Sell
2
-13
-87% -$3.18K ﹤0.01% 7369
2018
Q4 		$3K Buy
+15
New +$4.54K ﹤0.01% 6643
2017
Q1 		– Sell
-37
Closed -$19K – 7014
2016
Q4 		$19K Buy
+37
New +$16K ﹤0.01% 5655

Other funds holding XBIO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
LGF
LGT Group Foundation Vaduz, Liechtenstein $8.19B AUM 27.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWM
Darwin Wealth Management Tampa, Florida $365M AUM 22.69% 1-Year Est. Return

Barclays's XBIO Position: Q2 2025 in Review

Barclays sold out of Xenetic Biosciences (XBIO) in Q2 2025, closing a stake of 224 shares — an estimated $585 sold.

Barclays first reported a position in XBIO in Q4 2016 and held it in 5 quarters. The position peaked at $19K in Q4 2016. 9 funds tracked by Wall St. Rank hold XBIO as of Q2 2025.

  • Barclays reported no remaining Xenetic Biosciences position as of Q2 2025 after selling out during the quarter.
  • Barclays sold 224 Xenetic Biosciences shares in Q2 2025, an estimated $585.
  • Barclays first reported a position in Xenetic Biosciences in Q4 2016 and held it in 5 quarters.
  • Barclays's Xenetic Biosciences position peaked at $19K in Q4 2016.
  • 9 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.